Researchers at the University of Utah and National University Hospital Singapore have reported an objective imaging method for flagging limbic-predominant age-related TDP-43 encephalopathy, or LATE, in patients still living, and for seeing when it coexists with Alzheimer's disease. In the study, posted online by the Journal of Nuclear Medicine on 22 January 2026, Pei Ing Ngam and colleagues, with senior author Satoshi Minoshima, retrospectively analysed 944 [18F]FDG PET scans referred from cognitive disorder clinics at a single tertiary care centre. Of those, 13.0 percent were classified as probable LATE (2.4 percent LATE alone and 10.6 percent LATE together with Alzheimer's disease) and 23.7 percent as probable Alzheimer's disease without LATE.

The classification rests on three-dimensional stereotactic surface projection templates built from autopsy-confirmed cases: six brains with LATE neuropathologic change and 32 with Alzheimer's disease neuropathologic change, drawn from the Alzheimer's Disease Neuroimaging Initiative and University of Utah datasets. Scans were mapped as z scores against 20 control scans from people whose amyloid PET was negative, and a z score product index was used to sort each clinic case. Quantitative MRI volumetry ran alongside: the medial temporal lobe was the region most affected in the LATE-only group, while the orbitofrontal gyrus and lateral temporal lobe were most affected where LATE and Alzheimer's changes appeared together. In that mixed group, three quarters of cases showed metabolic change lateralised to the same hemisphere for both patterns, predominantly the left (P less than 0.001), with a matching left-dominant pattern of atrophy on MRI.

LATE matters because it is common and because it looks like Alzheimer's disease from the outside. The 2019 consensus report in Brain named the condition and described TDP-43 protein pathology in limbic structures as commonly observed in people past 80. A pooled analysis of 13 community-based and population-based autopsy cohorts, published in Acta Neuropathologica in 2022, found LATE neuropathologic change in almost 40 percent of participants, often but not always alongside Alzheimer's pathology. Clinical criteria for LATE were published in Alzheimer's and Dementia in January 2025, but there is still no fluid or PET tracer that detects TDP-43 in the living brain, which is why an inference drawn from glucose metabolism is being pursued at all.

The study's own stated limit is the thinness of its foundation. Six autopsy-confirmed LATE brains is a very small base on which to build a template, and none of the 944 clinic cases came with pathological confirmation, so every label in the analysis is a probability derived from imaging, not a diagnosis established at autopsy. The design was retrospective and single-centre, the control group numbered 20, and the authors call for further investigation of the apparent synergy between the two pathologies rather than presenting the method as settled.